|Bid||281.25 x 1000|
|Ask||281.49 x 800|
|Day's Range||276.83 - 283.97|
|52 Week Range||124.53 - 312.12|
|Beta (5Y Monthly)||1.00|
|PE Ratio (TTM)||61.41|
|Earnings Date||Apr 21, 2021 - Apr 26, 2021|
|Forward Dividend & Yield||0.68 (0.24%)|
|Ex-Dividend Date||Jan 19, 2021|
|1y Target Est||328.00|
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a second-quarter 2021 dividend of $0.17 per share. The dividend will be paid on May 5, 2021, to shareholders of record as of April 21, 2021.
Ladies and gentlemen, thank you for standing by and welcome to the fourth-quarter 2020 West Pharmaceutical Services earnings conference call. This morning, CEO Eric Green and CFO Bernard Birkett will review our financial results, provide an update on our business and present our financial outlook for the full year of 2021.
Shares of West Pharmaceutical Servs (NYSE:WST) moved higher by 0.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 63.41% year over year to $1.34, which beat the estimate of $1.12. Revenue of $580,200,000 up by 23.29% year over year, which beat the estimate of $543,670,000. Looking Ahead The upcoming fiscal year's EPS expected to be between $6.00 and $6.15. The upcoming fiscal year's revenue expected to be between $2,500,000,000 and $2,525,000,000. Conference Call Details Date: Feb 18, 2021 View more earnings on WST Time: 09:00 AM ET Webcast URL: https://edge.media-server.com/mmc/p/jd9idduz Price Action 52-week high: $312.12 Company's 52-week low was at $124.53 Price action over last quarter: Up 4.28% Company Description West Pharmaceutical Services is a Pennsylvania-based medical supplies company that operates as a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West develops, manufactures, and distributes elastomer-based supplies for the containment and administration of injectable drugs, including basic equipment such as syringes, stoppers, and plungers, along with somewhat more complicated devices including auto-injectors and other self-injection platforms. The company reports in two segments: proprietary products (75% of 2019 sales) and contract-manufactured products (25%). The firm generates 56% of its revenue from international markets and 44% from the United States. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 18, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.